Abstract
Sarcomas are a group of heterogeneous tumors that arise from mesenchymal tissue and account for approximately 1% of all adult solid malignancies diagnosed, although its incidence approaches 20% in pediatric cancers. Characterization of molecular abnormalities in patients with sarcomas, in particular the up-regulation of the receptor tyrosine kinase and the PI3K-AKT-mTOR pathway, loss or deletions of retinoblastoma (Rb) and p53 gene, increased VEGF expression and angiogenesis, dysregulation of apoptosis through Bcl-2 overexpression, along with oncogene mutations and activations, such as c-KIT in Gastrointestinal stromal tumors (GISTs), makes treatment with novel biological therapies a promising option. This review focuses on the molecular heterogeneity of soft tissue and bone sarcomas, novel biological therapies currently in clinical trials to target the various molecular pathways, and the potential biological agents in preclinical and early clinical development.
Keywords: Sarcoma, AKT, mTOR, IGF-1R, Ras, Apoptosis, VEGF and targeted therapy
Current Drug Targets
Title: Targeting Sarcomas: Novel Biological Agents and Future Perspectives
Volume: 10 Issue: 10
Author(s): Devalingam Mahalingam, Alain Mita, Kamalesh Sankhala, Ronan Swords, Kevin Kelly, Francis Giles and Monica M. Mita
Affiliation:
Keywords: Sarcoma, AKT, mTOR, IGF-1R, Ras, Apoptosis, VEGF and targeted therapy
Abstract: Sarcomas are a group of heterogeneous tumors that arise from mesenchymal tissue and account for approximately 1% of all adult solid malignancies diagnosed, although its incidence approaches 20% in pediatric cancers. Characterization of molecular abnormalities in patients with sarcomas, in particular the up-regulation of the receptor tyrosine kinase and the PI3K-AKT-mTOR pathway, loss or deletions of retinoblastoma (Rb) and p53 gene, increased VEGF expression and angiogenesis, dysregulation of apoptosis through Bcl-2 overexpression, along with oncogene mutations and activations, such as c-KIT in Gastrointestinal stromal tumors (GISTs), makes treatment with novel biological therapies a promising option. This review focuses on the molecular heterogeneity of soft tissue and bone sarcomas, novel biological therapies currently in clinical trials to target the various molecular pathways, and the potential biological agents in preclinical and early clinical development.
Export Options
About this article
Cite this article as:
Mahalingam Devalingam, Mita Alain, Sankhala Kamalesh, Swords Ronan, Kelly Kevin, Giles Francis and Mita M. Monica, Targeting Sarcomas: Novel Biological Agents and Future Perspectives, Current Drug Targets 2009; 10 (10) . https://dx.doi.org/10.2174/138945009789577990
DOI https://dx.doi.org/10.2174/138945009789577990 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Quinoline Imidoselenocarbamate EI201 Blocks the AKT/mTOR Pathway and Targets Cancer Stem Cells Leading to a Strong Antitumor Activity
Current Medicinal Chemistry Targeted Therapies for Autosomal Dominant Polycystic Kidney Disease
Current Medicinal Chemistry Recent Patents on Melanoma with Focus on Genetic Strategies
Recent Patents on Anti-Infective Drug Discovery Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy CD95 Signaling in Cancer Treatment
Current Pharmaceutical Design From Body Art to Anticancer Activities: Perspectives on Medicinal Properties of Henna
Current Drug Targets Strategies for the Design of Potent and Selective Kinase Inhibitors
Current Pharmaceutical Design Synthesis and In Vitro Antiproliferative Activity of Thiazole-Based Nitrogen Mustards: The Hydrogen Bonding Interaction between Model Systems and Nucleobases
Anti-Cancer Agents in Medicinal Chemistry Sodium Dependent Multivitamin Transporter (SMVT): A Potential Target for Drug Delivery
Current Drug Targets c-Myc: Linking Transformation and Genomic Instability
Current Molecular Medicine Sumoylation in Cellular Senescence and Aging
Current Molecular Medicine Anti-Inflammatory and Anti-Neoplastic Actions of Resveratrol
Current Nutrition & Food Science Tumor Stem Cell Niches: A New Functional Framework for the Action of Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery The Development of MetAP-2 Inhibitors in Cancer Treatment
Current Medicinal Chemistry Estrogen-Induced Genetic Alterations and Their Role in Carcinogenicity
Current Genomics Mesenchymal Stromal Cell Therapy for Cardio Renal Disorders
Current Pharmaceutical Design The Neuroprotective Role of PEDF: Implication for the Therapy of Neurological Disorders
Current Molecular Medicine Recent Progress in Research on Ribosome Inactivating Proteins
Current Protein & Peptide Science Seocalcitol (EB 1089) A Vitamin D Analogue of Anti-cancer Potential. Background, Design, Synthesis, Pre-clinical and Clinical Evaluation
Current Pharmaceutical Design Insertional Mutagenesis by Retroviral Vectors: Current Concepts and Methods of Analysis
Current Gene Therapy